Ken Griffin Entrada Therapeutics, Inc. Put Options Transaction History
Citadel Advisors LLC
- $559 Billion
- Q4 2024
Put Options
2 transactions
Others Institutions Holding TRDA
# of Institutions
104Shares Held
28.9MCall Options Held
40.3KPut Options Held
4.1K-
Baker Bros. Advisors LP New York, NY4.87MShares$63.5 Million0.93% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.41MShares$57.5 Million33.83% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.38MShares$57.1 Million60.89% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.9MShares$37.9 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X02.08MShares$27.1 Million0.02% of portfolio
About Entrada Therapeutics, Inc.
- Ticker TRDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,368,500
- Market Cap $409M
- Description
- Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...